The British Toxicology Society (BTS) has announced that its recently-launched mid-career achievement award will be named after Professor Kevin Park, in recognition of his pioneering work across the disciplines of clinical and basic toxicology and pharmacology, drug safety and medicinal chemistry for nearly 50 years.
The award honours Professor Park’s contribution to improving drug safety nationally and internationally, making major impacts in terms of benefiting individual patients, public health, Government policy and the pharmaceutical industry.
During his time at the University, Kevin was Head of the Department of Pharmacology and Therapeutics and Head of the Institute for Translational Medicine and established the first national MRC-funded Centre for the study of the safety of medicines, one of only two such centres in the World. Kevin also sat on the BTS Executive Committee for six years, was a Fellow of the Society and was awarded its prestigious Barnes Prize in 2017.
When Kevin Park passed away in 2022, the fields of toxicology, drug safety and pharmacology lost one of their greatest original thinkers and scientists. The Department of Pharmacology and Therapeutics and Institute of Systems, Molecular and Integrative Biology (ISMIB) are delighted that the BTS has recognised his contributions to these fields through the naming of the mid-career achievement award in his honour, an award that he would have particularly appreciated given his dedication to helping to develop the careers of fellow scientists.
For details of the award, please visit: https://www.thebts.org/awards-bursaries/mid-career-achievement-award/